Canaccord Genuity Maintains Buy on Intellia Therapeutics, Raises Price Target to $58

Benzinga Newsdesk www.benzinga.com Positive 87.1%

Neg 0% Neu 0% Pos 87.1%

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $48 to $58.